证券代码：000766 证券简称：通化金马 公告编号：2023-46 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续二 个交易日（2023 年 9 月 11 日、9 月 12 日）日收盘价格涨幅偏离值累计超过 20%。 根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票异常波动，经通过电话、现场问询等方式对公司控股股东、实 际控制人、董事会、管理层进行核实，现对有关核实情况说明如下： 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 4、2023 年 8 月 31 日，公司披露了《关于完成国家 I.I 类新药琥珀八氢氨 吖啶片 III 期临床试验盲态数据审核的公告》，集团公司及全资子公司长春华洋 高科技有限公司自主研发 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-45 通化金马药业集团股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 通化金马药业集团股份有限公司（以下简称"公司"）股票交易价格连续二 个交易日（2023 年 8 月 30 日、8 月 31 日）日收盘价格涨幅偏离值累计超过 20%。 根据深圳证券交易所的有关规定，该情形属于股票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票异常波动，经通过电话、现场问询等方式对公司控股股东、实 际控制人、董事会、管理层进行核实，现对有关核实情况说明如下： 1、公司前期披露的信息未发现需要更正、补充之处。 2、公司未发现近期公共传媒报道可能或已经对公司股票交易价格产生较大 影响的未公开重大信息。 3、目前公司经营情况及内外部经营环境未发生重大变化。 4、2023 年 8 月 31 日，公司披露了《关于完成国家 I.I 类新药琥珀八氢氨 吖啶片 III 期临床试验盲态数据审核的公告》，集团公司及全资子公司长春华洋 高科技有限公司自主研发 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥728,491,083.33, representing a 5.01% increase compared to ¥693,725,150.23 in the same period last year[11]. - Net profit attributable to shareholders was ¥10,776,911.31, a significant increase of 43.12% from ¥7,529,859.90 in the previous year[11]. - The net profit after deducting non-recurring gains and losses reached ¥7,709,212.42, which is a 107.07% increase compared to ¥3,722,972.58 in the same period last year[11]. - The basic earnings per share rose to ¥0.0112, up 43.59% from ¥0.0078 in the previous year[11]. - The total operating revenue for the first half of 2023 reached CNY 728,491,083.33, an increase of 5.7% compared to CNY 693,725,150.23 in the same period of 2022[89]. - Total operating costs amounted to CNY 710,963,901.65, up from CNY 684,018,066.24, reflecting a year-on-year increase of 3.9%[90]. - Net profit for the first half of 2023 was CNY 10,304,366.03, compared to CNY 7,076,237.91 in the previous year, indicating a significant improvement[90]. - The total comprehensive income for the first half of 2023 was CNY 10,304,366.03, compared to CNY 7,076,237.91 in the first half of 2022, marking an increase of around 45%[91]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,534,138,987.01, a decrease of 3.22% from ¥4,685,114,987.39 at the end of the previous year[11]. - The company's total liabilities decreased to CNY 2,155,333,378.35 from CNY 2,316,613,744.76, a reduction of about 7%[87]. - Cash and cash equivalents decreased to ¥229,111,387.06, making up 5.05% of total assets, down from 7.19% the previous year[29]. - Accounts receivable increased to ¥436,538,415.65, representing 9.63% of total assets, up from 9.05% year-over-year[29]. - Inventory stood at ¥378,219,837.23, accounting for 8.34% of total assets, slightly up from 8.14%[29]. - The company's total liabilities at the end of the reporting period were 1,000,000,000.00 CNY, reflecting a stable financial position[104]. Cash Flow - The net cash flow from operating activities decreased by 29.25% to ¥41,102,119.70 from ¥58,097,322.65 in the same period last year[11]. - The company's cash flow from operating activities for the first half of 2023 was approximately ¥890,090, compared to ¥39,493,373 in the same period of 2022, indicating a significant decrease[97]. - The total cash outflow for operating activities was ¥425,916,612, compared to ¥325,234,992 in the first half of 2022, indicating an increase of approximately 30.9%[97]. - The net cash flow from investment activities was ¥95,211,614, a recovery from a negative cash flow of ¥6,292,861 in the first half of 2022[98]. Research and Development - The company’s R&D investment increased by 17.50% to ¥25,093,147.80 from ¥21,355,042.90 in the previous year, indicating a strong commitment to new drug development[24]. - Research and development expenses increased to CNY 21,717,792.04, up from CNY 18,946,335.68, marking a rise of 14.7%[90]. - The company is actively engaged in new product development and technological innovation to enhance product competitiveness[19]. Market and Industry - The pharmaceutical industry in China is expected to continue growing due to increasing health awareness and an aging population[16]. - The government is implementing policies to support the development of traditional Chinese medicine, which presents new opportunities for the company[16]. - The company operates in various therapeutic areas, including oncology, cardiovascular, and digestive systems, with leading products such as compound Lactobacillus tablets and rheumatism pain relief capsules[16]. Environmental Compliance - The company has established a quality management system to ensure compliance with GMP standards, controlling quality across all production stages[42]. - The company is classified as a key pollutant discharge unit and adheres to strict environmental regulations and industry standards[47]. - The company reported a stable operation of its wastewater treatment facility, processing a total of 139,622 tons of wastewater in the first half of 2023, with a COD average effluent concentration of 16.95 mg/L and ammonia nitrogen average effluent concentration of 0.139 mg/L[51]. - The company invested 8.2 million yuan in 2016 to expand its wastewater treatment capacity to 1,000 tons per year, which was completed and put into operation in August 2018[51]. Shareholder Information - The company reported a total of 966,494,707 shares outstanding, with 12.20% being limited sale condition shares and 87.80% being unrestricted sale condition shares[70]. - The largest shareholder, Yu Lanjun, holds 190,000,000 shares, representing 19.66% of the total shares, with 150,000,000 shares pledged[72]. - The company has not reported any changes in accounting policies or prior period error corrections for this reporting period[107]. Risks and Challenges - The company faces various risks as outlined in the report, and investors are advised to read the relevant sections carefully[2]. - The company faces risks from pharmaceutical industry policies, which may impact sales volume and pricing due to reforms in drug approval and procurement policies[41]. - New product development is a high-risk area, with long cycles and uncertainties affecting market prospects and economic returns[42]. Corporate Governance - The company has not engaged in any major related party transactions during the reporting period[59]. - The company has not provided any guarantees to related parties during the reporting period[64]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[81].

证券代码：000766 证券简称：通化金马 公告编号：2023-39 通化金马药业集团股份有限公司 第十一届董事会 2023 年第一次临时会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 1. 通化金马药业集团股份有限公司第十一届董事会 2023 年第一次临时会议于 2023 年 8 月 15 日以电子邮件形式送达全体董事。 2. 2023 年 8 月 16 日下午 15 时以现场和通讯方式召开。 3.会议应到董事 9 人，实到董事 9 人。 4. 会议由董事长张玉富先生主持。监事会成员及部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 审议通过了关于收购控股子公司长春华洋自然人股东股权的议案 近几年，由于国家新药审评、审批要求、管理政策发生改变，尤其是 2019 年 12 月 1 日施行的《中华人民共和国药品管理法(2019 年修订)》，在第六条规定中， 明确了国家实行药品上市许可持有人制度，标志着药品上市许可持有人（MAH）制度 开 ...

关于收购控股子公司长春华洋自然人股东股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2023 年 8 月 16 日，通化金马药业集团股份有限公司（以下简称"公司"） 第十一届董事会 2023 年第一次临时会议审议通过了《关于收购控股子公司长春 华洋自然人股东股权的议案》。 一、交易概述 1、交易的基本情况 证券代码：000766 证券简称：通化金马 公告编号：2023-40 通化金马药业集团股份有限公司 长春华洋高科技有限公司（以下简称"长春华洋"）及其控股子公司江苏神 尔洋高科技有限公司（以下简称"神尔洋"）共同拥有治疗轻、中度阿尔茨海默 病的化药 1.1 类新药琥珀八氢氨吖啶片的全部知识产权，并已获准开展该新药的 III 期临床研究。为拓宽公司发展空间，提升公司实力，2016 年 1 月 18 日，公 司与长春华洋及其全体股东、神尔洋及其全体股东签了《关于长春华洋高科技有 限公司与江苏神尔洋高科技有限公司之收购框架协议》（以下简称"《框架协议》"） 及《关于江苏神尔洋高科技有限公司之股权转让协议》（以下简称"《神尔洋股权 转让协议》"）、《关于 ...

广发证券股份有限公司 关于通化金马药业集团股份有限公司 部分限售股份解除限售的核查意见 广发证券股份有限公司（以下简称"广发证券"或"独立财务顾问"）作为通化 金马药业集团股份有限公司（以下简称"通化金马"、"上市公司"或"公司"）2015 年发行股份及支付现金购买资产并募集配套资金暨关联交易（以下简称"前次重 组"）的独立财务顾问，对通化金马本次限售股份上市流通事项进行了审慎核查， 现将核查情况及核查意见发表如下： 一、本次解除限售的股份取得的基本情况及后续股本变动情况 通化金马股东北京晋商联盟投资管理有限公司（以下简称"北京晋商"）因 与财通证券资产管理有限公司金融借款合同纠纷，其所持有公司 70,000,000 股有 限售条件的股份被浙江省杭州市中级人民法院公开拍卖，上述股份已于 2023 年 7 月 11 日通过淘宝网司法拍卖网络平台竞价全部成交。其中陈新凯以最高应价 胜出竞得北京晋商被拍卖的公司 10,000,000 股股份；余奉昌以最高应价胜出合计 竞得北京晋商被拍卖的公司 20,000,000 股股份；魏巍以最高应价胜出合计竞得北 京晋商被拍卖的公司 20,000,000 股股份；韩莉莉以最高应 ...

证券代码：000766 证券简称：通化金马 公告编号：2023-38 通化金马药业集团股份有限公司 关于部分限售股份解除限售的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示 1、通化金马药业集团股份有限公司本次解除限售股份数量为 70,000,000 股，占公司目前股份总数 966,494,707 股的 7.2427%。 2、本次申请解除股份限售的股东 4 名。 3、本次有限售条件流通股上市流通日为 2023 年 8 月 18 日。 一、本次解除限售的股份取得的基本情况及后续股本变动情况 通化金马药业集团股份有限公司（以下简称"公司"、"通化金马""上市公 司"）股东北京晋商联盟投资管理有限公司（以下简称"北京晋商"）因与财通证 券资产管理有限公司金融借款合同纠纷，其所持有公司 70,000,000 股有限售条 件的股份被浙江省杭州市中级人民法院公开拍卖，上述股份已于 2023 年 7 月 11 日通过淘宝网司法拍卖网络平台竞价全部成交。其中陈新凯以最高应价胜出竞得 北京晋商被拍卖的公司 10,000,000 股股份；余奉昌以最高应价胜出 ...

Group 1: Company Overview and Activities - The company is Tonghua Jinma Pharmaceutical Group Co., Ltd., with stock code 000766 [1] - The investor relations activity was held on May 22, 2023, via an online platform [1] - Participants included the company's board members and investors [1] Group 2: New Drug Development - The new drug, Amber Hydrogen Amino Acids Tablets, is in Phase III clinical trials, currently undergoing inspection and correction [1][2][3] - The company is closely monitoring the drug's development and will disclose information as required by regulations [1][2][3] - Reports suggest that 13 products, including the new drug, are expected to be launched before 2024 [1] Group 3: Financial and Operational Concerns - The company is addressing short-term and long-term debt management to reduce annual interest expenses [2] - Marketing expenses are currently aligned with sales scale, but the company plans to enhance management to control these costs [2] - The liquidity issues in the secondary market are acknowledged, and the company aims to maintain steady operational performance [2] Group 4: Regulatory and Disclosure Practices - The company emphasizes compliance with information disclosure obligations regarding new drug approvals and developments [1][2][3] - There is a focus on maintaining confidentiality around new drug progress, leading to standardized responses to inquiries [3]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，通化金马药业集团股份有限公司（以下 简称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限 公司共同举办的"2023 年吉林辖区上市公司网上集体业绩说明会"，现将有关事 项公告如下： 本次集体业绩说明会将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景网"投资者关系互动平台"（http://ir.p5w.net）参 与公司业绩说明会,时间为 2023 年 5 月 22 日（星期一）14:00 至 16:00。 届时公司董事兼总经理战红君先生、独立董事吕桂霞女士、董事会秘书贾伟 林先生、财务总监于军先生及工作人员将通过网络在线问答互动的形式，与投资 者就 2022 年经营业绩等投资者关注的问题进行交流。期间，公司高管将全程在 线，实时回答投资者的提问。投资者可于 2023 年 5 月 19 日（星期五）17：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页面， 欢迎广大投资者积极参与。 证券代码：0 ...

Financial Performance - The company's revenue for Q1 2023 was ¥308,557,426.09, a decrease of 13.70% compared to ¥357,550,409.09 in the same period last year[28]. - Total operating revenue for the current period is $308.56 million, down 13.68% from $357.55 million in the previous period[37]. - Operating profit for the current period is $5.73 million, down 13.76% from $6.65 million in the previous period[38]. - Net profit attributable to shareholders was ¥6,962,447.85, representing a 20.29% increase from ¥5,788,129.66 year-on-year[28]. - Net profit increased to $6.72 million, up 20.38% from $5.58 million in the previous period[38]. - Basic earnings per share increased by 20.00% to ¥0.0072 from ¥0.0060 in the same period last year[28]. - Basic and diluted earnings per share for the current period are both $0.0072, compared to $0.0060 in the previous period[39]. Assets and Liabilities - Total assets decreased from CNY 4,685,114,987.39 to CNY 4,500,521,306.00, a decline of about 3.9%[9]. - Total assets at the end of the reporting period were ¥4,500,521,306.00, a decrease of 3.94% from ¥4,685,114,987.39 at the end of the previous year[28]. - Total liabilities decreased from CNY 2,316,613,744.76 to CNY 2,125,298,762.67, a reduction of approximately 8.2%[9]. - The company’s long-term borrowings remained stable at CNY 1,563,550,000.00[9]. Cash Flow and Equivalents - Cash and cash equivalents decreased from CNY 336,821,630.18 at the beginning of the year to CNY 219,533,073.55 by March 31, 2023, representing a decline of approximately 34.8%[7]. - Cash and cash equivalents decreased by 34.82% to ¥219,533,073.55 due to loan repayments during the reporting period[30]. - The net increase in cash and cash equivalents was -$18,441,114.70, compared to a decrease of -$44,011,207.79 in the prior period[55]. - The ending balance of cash and cash equivalents stood at $216,764,113.25, down from $235,205,227.95 at the beginning of the period[55]. Income and Expenses - The company reported a total non-operating income of CNY 2,213,254.24 during the reporting period[2]. - The company reported a government subsidy income of CNY 2,386,717.51 during the reporting period[2]. - Other income rose by 38.15% to ¥2,386,717.51, mainly due to increased government subsidies[30]. - Total operating costs decreased to $300.49 million, a reduction of 12.73% from $344.32 million in the previous period[37]. - Research and development expenses increased to $9.33 million, up 11.15% from $8.39 million in the previous period[37]. - Sales expenses decreased to $162.41 million, down 18.63% from $199.60 million in the previous period[37]. Financing Activities - The company applied for a loan of up to CNY 90 million from Guangfa Bank to support its operational needs[6]. - Short-term borrowings increased significantly by 419.59% to ¥130,117,500.00, attributed to new bank loans[30]. - The net cash flow from financing activities was negative at -$118.78 million, a significant decrease of 170.80% compared to -$43.86 million in the previous period[46]. - Cash inflow from financing activities totaled $130,000,000.00, with cash outflow for debt repayment reaching $227,200,000.00, resulting in a net cash flow from financing activities of -$118,784,542.88[55]. Equity - The company’s total equity increased from CNY 2,368,501,242.63 to CNY 2,375,222,543.33, an increase of about 0.3%[9]. - The company's total equity attributable to shareholders was ¥2,343,821,861.62, a marginal increase of 0.30% from ¥2,336,859,413.77 at the end of the previous year[28]. - The weighted average return on net assets was 0.30%, slightly up from 0.25% in the previous year[28].